Because HSP90 inhibitors block multiple pathways crucial to MM survival [7,9,20], the combination of TAS-116 and dabrafenib enhances the anti-MM effect in RAS-mutated and wild-type BRAF MM cells via a mechanism other than ERK pathway inhibition. This evidence concerns the gene BRAF and Miyoshi myopathy.